The ZNF217 biomarker predicts low-and high-risk oncotype DX® recurrence score in ER-positive invasive breast cancers

Cohen, P. A., Loudig, O., Liu, C., Albanese, J., & Fineberg, S. (2019). The ZNF217 biomarker predicts low-and high-risk oncotype DX® recurrence score in ER-positive invasive breast cancers. Frontiers in Pharmacology, 10(MAY). https://doi.org/10.3389/fphar.2019.00524